This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignees: Assistance Publique-Hopitaux De Paris, Centre National De La Recherche Scientifique, National Institute of Health and Medical Research. Active years: 2022.
Company Filing History:
1 out of 331 
1 out of 5,383 
1 out of 1,853 
Years Active: 2022
Title: Anne Lombes: Innovator in Cellular Energy Metabolism
Introduction
Anne Lombes is a distinguished inventor based in Paris, France. She has made significant contributions to the field of cellular energy metabolism, particularly in the context of medically assisted procreation. Her innovative work has the potential to enhance the success rates of fertility treatments.
Latest Patents
Anne Lombes holds a patent for the "Use of a cyclic tripeptide for improving cellular energy metabolism." This invention relates to the use of a cyclic peptide that reproduces a binding site of fertilin beta to the oocyte integrin. The cyclic peptide, specifically the tripeptide FEEc, is designed to stimulate the energy metabolism of gametes or embryonic cells. This is particularly relevant in medically assisted procreation protocols, as it promotes the in vitro maturation of oocytes, increases fertilization rates, and improves birth rates.
Career Highlights
Throughout her career, Anne Lombes has worked with notable institutions such as Assistance Publique-Hôpitaux de Paris and Université de Paris. Her research and innovations have garnered attention in the scientific community, contributing to advancements in reproductive health.
Collaborations
Anne has collaborated with esteemed colleagues, including Jean-Philippe Wolf and Morgane Bomsel. These partnerships have further enriched her research and development efforts in the field.
Conclusion
Anne Lombes is a pioneering inventor whose work in cellular energy metabolism is making a significant impact in the realm of fertility treatments. Her innovative approaches and collaborations continue to advance the field, offering hope to many seeking assistance in procreation.